TheraRadar
Clinical-Stage Companies / Medigen Vaccine Biologics

Medigen Vaccine Biologics

Pre-Approval PRO BETA
17
Total Trials
6
Phase 3
9
Phase 2
1
Recruiting
176
Score

Pipeline by Phase

Phase 3
6
Phase 2
9
Phase 1
3

Therapeutic Focus

Covid19 Vaccine COVID-19 Vaccine Enterovirus 71 Inactivated Vaccine Enterovirus 71 Infection COVID-19

Clinical Trials (17)

NCT07178522 Phase 3 RECRUITING

A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years

Started: 6/25/2025

NCT05198596 Phase 3 COMPLETED

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

Started: 7/30/2022

NCT05426343 Phase 3 COMPLETED

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

Started: 7/9/2022

NCT05011526 Phase 3 COMPLETED

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

Started: 10/8/2021

NCT03865238 Phase 3 COMPLETED

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of an EV71 Vaccine

Started: 4/23/2019

NCT03718468 Phase 3 COMPLETED

A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine

Started: 10/30/2018

NCT05197153 Phase 2 COMPLETED

A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19

Started: 1/22/2022

NCT05048849 Phase 2 COMPLETED

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study

Started: 7/19/2021

NCT04822025 Phase 2 COMPLETED

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults

Started: 5/20/2021

NCT05038618 Phase 2 COMPLETED

A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study

Started: 8/2/2021

NCT04951388 Phase 2 COMPLETED

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents

Started: 7/22/2021

NCT04695652 Phase 2 COMPLETED

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult

Started: 12/30/2020

NCT03485144 Phase 2 COMPLETED

A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan

Started: 12/12/2017

NCT02200237 Phase 2 COMPLETED

A Clinical Study for Inactivated Vaccine Against EV71

Started: 9/1/2014

NCT05216601 Phase 1 COMPLETED

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19

Started: 5/6/2022

NCT04487210 Phase 1 COMPLETED

A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19

Started: 10/7/2020

NCT02436928 Phase 1 COMPLETED

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

Started: 4/1/2015

Drug Candidates

Envacgen® MVC-COV1901 AZD1222 Half dose of MVC-COV1901 Full dose of MVC-COV1901 Half dose of mRNA-1273 MVC-COV1901(Beta)-15 MVC-COV1901(Beta)-25 MVC-COV1901(S protein with adjuvant) MVC-COV1901 (High-Dose)
Activity Status: Active
Last Trial Started: 6/25/2025
Last Trial Ended: 3/30/2023
Trials (12 months): 1
Completed Trials: 16
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.